pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

438 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1156Endpoints875BioPharma Dive339BioSpace293Fierce Biotech277onclive165raps104globenewswire health73
therapy area
allOncology7353Rare Disease1826Cardiology1672Immunology1456Hematology1302Vaccines1173Pulmonology1084Psychiatry & CNS858
  • Clinical Scenario Presentation and Treatment Approach for Progressive Disease
    Experts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.
    onclive · 4mo ago↗ source
  • Opinion: STAT+: Ambiguous loss: a peculiar kind of grief in dementia care
    Ambiguous loss is at the heart of the dementia illness experience.
    STAT · 4mo ago↗ source
  • Opinion: Dr. Glaucomflecken wants to make a stink
    “They don’t want this kind of scrutiny”: Why Dr. Glaucomflecken is getting involved in protests over an Oregon hospital system’s emergency department.
    STAT · 4mo ago↗ source
← prev
page 17 of 18
next →
fda recalls67
fda medwatch60
fda press38
Ophthalmology491
Pain469
Endocrinology & Metabolism466
Infectious Disease437
  • Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?
    The psychedelics field is getting what it has long wanted. Now it has to step up.
    STAT · 4mo ago↗ source
  • The Type of Fat—Not the Amount—Fuels Pancreatic Cancer
    Research from Yale Cancer Center showed that the type of fat consumed may matter more than amount in pancreatic cancer.
    onclive · 4mo ago↗ source
  • STAT+: Are analysts too quick to gloss over Lilly’s liver case?
    Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
    STAT · 4mo ago↗ source
  • Cytokinetics heart drug scores in closely watched trial
    Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar market opportunity.
    BioPharma Dive · 4mo ago↗ source
  • Cytokinetics succeeds where Bristol Myers failed in heart muscle disease
    Cytokinetics’ pill for a heart muscle disorder called hypertrophic cardiomyopathy could see its addressable market double after it succeeded in a pivotal trial for another form of the disease. The…
    Endpoints · 4mo ago↗ source
  • STAT+: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease
    A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost for sales.
    STAT · 4mo ago↗ source
  • With $97M, Latus pursues a different kind of Huntington’s gene therapy
    The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.
    BioPharma Dive · 4mo ago↗ source
  • Opinion: What do medical students think about their education?
    “No one's pulling the pieces together”: a conversation with medical students about preventive care education.
    STAT · 4mo ago↗ source
  • Opinion: STAT readers on MAHA activists, perimenopause, and diversity in medical school
    “Unfortunately, the resources don't exist to take every flat-earther to the International Space Station to change their mind,” a STAT reader writes.
    STAT · 4mo ago↗ source
  • Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstood
    J. Craig Venter, the scientist whose relentless ambition helped turn genetics from an artisanal trade into an industrialized information machine, died at 79.
    STAT · 4mo ago↗ source
  • STAT+: In her own words: Surgeon general nominee Nicole Saphier expresses enthusiasm and caution for MAHA
    Examining the past statements and writings of Trump's third surgeon general nominee, Dr. Nicole Saphier, on vaccines, autism, peptides, diet and more.
    STAT · 4mo ago↗ source
  • Trump drops Casey Means as surgeon general nominee, opts for radiologist Nicole Saphier
    Trump slammed Sen. Bill Cassidy for blocking his surgeon general pick, as he nominated a replacement.
    STAT · 4mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Supreme Court hearing on ‘skinny labels,’ AstraZeneca U.K. expansion, and more
    AstraZeneca will resume expansion of its U.K. R&D operations after the trade deal with the U.S. included measures to lift U.K. drug spending
    STAT · 4mo ago↗ source
  • STAT+: New obesity tool aims to predict risk of 18 serious complications
    A new tool, OBSCORE, is meant to better define who's at risk for obesity complications, going beyond BMI to include family history, diet, and more.
    STAT · 4mo ago↗ source
  • STAT+: Supreme Court justices appear to signal ‘skinny labeling’ can survive
    At Wednesday's argument, the justices did not appear to question whether skinny labeling is valid.
    STAT · 4mo ago↗ source
  • AbbVie faces questions about Skyrizi competition from J&J
    Threats to AbbVie's immunology dominance took center stage on the company's first-quarter earnings call Wednesday morning, as analysts pressed executives on their defense strategy. The heart of the…
    Endpoints · 4mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about the FDA speeding up trials, a Supreme Court hearing on ‘skinny labels,’ and more
    The FDA announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials conducted by AstraZeneca and Amgen
    STAT · 4mo ago↗ source
  • STAT+: AIDS group sues Trump administration over undisclosed agreement with Gilead
    The AIDS advocacy group PrEP4All has sued the Trump administration over an undisclosed agreement with Gilead.
    STAT · 4mo ago↗ source
  • Pfizer delays patent cliff for blockbuster Vyndamax
    Pfizer is staving off Vyndamax competition for another two years. The drug, also known as tafamidis, is among Pfizer’s top three best-selling medicines and vaccines. Vyndamax is approved for a hear…
    Endpoints · 4mo ago↗ source
  • Pfizer deals extend patent life for a top-selling rare disease drug
    Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
    BioPharma Dive · 4mo ago↗ source
  • STAT+: Supreme Court to hear case about ‘skinny labeling’ and generic access
    The Supreme Court Wednesday will hear oral arguments about a simmering controversy over so-called skinny labels, with implications for the availability of generics.
    STAT · 4mo ago↗ source
  • FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
    Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.
    BioPharma Dive · 4mo ago↗ source